ArticleJournal of kidney cancer and VHL2025

Meet-URO Score Validation in Real-world Patients with Metastatic Renal Cell Carcinoma Receiving First-line Pembrolizumab Plus axitinib: A Subanalysis of the Prospective ProPAXI Study.

Giulia Airò et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.